<DOC>
	<DOCNO>NCT00358020</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy association Melphalan/Prednisone/Thalidomide/VELCADE ( MPTV ) salvage treatment advance refractory myeloma patient . This association might increase response rate achieve standard oral MP regimen .</brief_summary>
	<brief_title>Melphalan , Prednisone , Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients</brief_title>
	<detailed_description>In Multiple Myeloma ( MM ) patient , conventional treatment oral combination melphalan prednisone ( MP ) . thalidomide widely use myeloma , prove clinical effective refractory myeloma patient , act sinergistically association dexamethasone . In newly diagnose patient , combination oral MP plus thalidomide increase partial complete response rate.Bortezomib represent novel class anti-cancer drug , active patient multiple myeloma refractory conventional chemotherapy . In preliminary report , combination VELCADE Thalidomide induce remarkable 60 % PR rate advance refractory myeloma patient . This study evaluate safety efficacy association Melphalan/ Prednisone/Thalidomide/VELCADE ( MPTV ) salvage treatment advance refractory myeloma patient . This association might increase response rate achieve standard oral MP regimen .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patient legally consent age define local regulation . Patient , investigator ( ) opinion willing able comply protocol requirement . Patient give voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . Female patient either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male patient agree use acceptable method contraception ( i.e. , condom abstinence ) duration study . Patient previously diagnose multiple myeloma base standard criterion . Patient relapse refractory one two line treatment include highdose chemotherapy stem cell support , conventional polichemotherapy , thalidomide melphalanbased regimen . Patient measurable disease , define follow : quantifiable serum monoclonal protein value ( generally , necessarily , great 1 g/dL IgG MProtein great 0.5 g/dL IgA MProtein ) , applicable , urine lightchain excretion &gt; 200 mg/24 hour . Patient Karnofsky performance status ≥60 % . Patient lifeexpectancy &gt; 3 month . Patient follow laboratory value within 14 day Baseline ( day 1 Cycle 1 , study drug administration ) : Platelet count ≥75 x 109/L without transfusion support within 7 day test . Absolute neutrophil count ( ANC ) ≥ 0.75 x 109/L without use growth factor . Corrected serum calcium ≤14 mg/dL ( 3.5 mmol/L ) . Aspartate transaminase ( AST ) : ≤ 2.5 x upper limit normal ( ULN ) . Alanine transaminase ( AST ) : ≤ 2.5 x ULN . Total bilirubin : ≤ 1.5 x ULN . Calculated measured creatinine clearance : ≥20 mL/minute . Patient absolute neutrophil count &lt; 0.75 × 109/L within 14 day enrollment . Patient calculate measured creatinine clearance &lt; 20 mL/minute within 14 day enrollment . Patient ≥Grade 2 peripheral neuropathy within 14 day enrollment . Patient known hypersensitivity bortezomib , boron , mannitol thalidomide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>MYELOMA , THALIDOMIDE , BORTEZOMIB</keyword>
</DOC>